The scPagwas analysis of single-cell sequencing combined with Bayesian deconvolution with SMR Reveals Tumor Heterogeneity and Predicts Immunotherapy Response in Neuroblastoma.
5 affiliations
- 1Department of Pediatric Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, China.
- 2Tianjin's Clinical Research Center for Cancer, China.
- 3Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China.
- 4Department of Histology and Embryology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.
- 5Interdisciplinary Center, Shandong University, China.
Abstract
Objective
High-risk neuroblastoma, the predominant driver of pediatric cancer deaths, is marked by marked intratumoral heterogeneity that fuels therapy resistance. To predict response to and targets for immunotherapy, we use single-cell and bulk RNA sequencing data to reveal tumor heterogeneity in neuroblastoma, and to identify prognostic genes for neuroblastoma.Methodology
Single-cell data were analyzed for trait-associated subpopulations and genes using single-cell Pathway-based genome-wide association study (scPagwas), and TARGET data were analyzed for differentially expressed genes. Bayesian deconvolution of trait-related subpopulations was performed to analyze the association between differences in convoluted cellular fractions, survival, and clinical traits. Further analysis of the association of convoluted cellular fractions with various immune-related gene sets with immunotherapy. Core gene validation survival, function, and correlation analysis of a convolutional cell-based screen for neuroblastoma. Summary-data-based Mendelian Randomization (SMR) was used to further validate the core genes.Results
Multiple cell subpopulations such as IL7R/CD4⁺ T cells were identified in neuroblastoma based on single-cell sequencing data. Among them, the FYB/CD4⁺ T cell subpopulation is strongly associated with multiple features in neuroblastoma. The convoluted cellular fractions obtained from this cell subpopulation also correlate with several features of neuroblastoma and can predict response to immunotherapy. Core genes from convoluted cell-based screens have been associated with a variety of traits including survival and cell function in neuroblastoma.Conclusions
Neuroblastomas have distinct cell subpopulations, and neuroblastomas deficient in the FYB/CD4⁺ T cell subpopulation have poorer survival and impaired immune cell infiltration and response to immunotherapy. Several genes, like RGS1, could play a central role in neuroblastoma development.
Related
- DeCoRE: A computational method to resolve RNA structural heterogeneity from RNA structure probing data by direct RNA sequencing
- ReadsRatio: a facile method for cell type deconvolution with cross-platform applications
- Longitudinal single-cell analysis identifies a chemotherapy-suppressed proliferative program associated with adverse prognosis in neuroblastoma
- Chroma-Agent-Alpha: An Open-Source Framework for Automated Chromatography Preprocessing, GNN-Based Peak Deconvolution, and FAIR Data Lineage
- Biologically informative not available deconvolution excavates hidden features in proteomics datasets.
BibTeX
@article{jia2026scpagwas,
title = {{The scPagwas analysis of single-cell sequencing combined with Bayesian deconvolution with SMR Reveals Tumor Heterogeneity and Predicts Immunotherapy Response in Neuroblastoma.}},
author = {Changlin Jia and Daowei Wang and Changfeng Jia and Pan Wang and Yun Liu and Qiang Zhao},
journal = {Journal of Cancer},
year = {2026},
month = sep,
doi = {10.7150/jca.138740},
url = {https://europepmc.org/article/MED/42910399},
note = {CC BY},
}
RIS
TY - JOUR
TI - The scPagwas analysis of single-cell sequencing combined with Bayesian deconvolution with SMR Reveals Tumor Heterogeneity and Predicts Immunotherapy Response in Neuroblastoma.
AU - Changlin Jia
AU - Daowei Wang
AU - Changfeng Jia
AU - Pan Wang
AU - Yun Liu
AU - Qiang Zhao
PY - 2026
DA - 2026/09/28
JO - Journal of Cancer
DO - 10.7150/jca.138740
UR - https://europepmc.org/article/MED/42910399
AB - Objective High-risk neuroblastoma, the predominant driver of pediatric cancer deaths, is marked by marked intratumoral heterogeneity that fuels therapy resistance. To predict response to and targets for immunotherapy, we use single-cell and bulk RNA sequencing data to reveal tumor heterogeneity in neuroblastoma, and to identify prognostic genes for neuroblastoma.Methodology Single-cell data were analyzed for trait-associated subpopulations and genes using single-cell Pathway-based genome-wide association study (scPagwas), and TARGET data were analyzed for differentially expressed genes. Bayesian deconvolution of trait-related subpopulations was performed to analyze the association between differences in convoluted cellular fractions, survival, and clinical traits. Further analysis of the association of convoluted cellular fractions with various immune-related gene sets with immunotherapy. Core gene validation survival, function, and correlation analysis of a convolutional cell-based screen for neuroblastoma. Summary-data-based Mendelian Randomization (SMR) was used to further validate the core genes.Results Multiple cell subpopulations such as IL7R/CD4⁺ T cells were identified in neuroblastoma based on single-cell sequencing data. Among them, the FYB/CD4⁺ T cell subpopulation is strongly associated with multiple features in neuroblastoma. The convoluted cellular fractions obtained from this cell subpopulation also correlate with several features of neuroblastoma and can predict response to immunotherapy. Core genes from convoluted cell-based screens have been associated with a variety of traits including survival and cell function in neuroblastoma.Conclusions Neuroblastomas have distinct cell subpopulations, and neuroblastomas deficient in the FYB/CD4⁺ T cell subpopulation have poorer survival and impaired immune cell infiltration and response to immunotherapy. Several genes, like RGS1, could play a central role in neuroblastoma development.
SN - 1837-9664
ER -